About Isconova
Isconova is a Healthcare company based in Uppsala (Sweden) founded in 1999, and was acquired by Novavax in June 2013. Vaccine adjuvants are developed for infectious diseases and veterinary applications. Isconova has raised $5.02 million across 1 funding round from investors including Novavax and InnovationsKapital. Isconova has completed 1 acquisition, including Nordic Vaccine. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Diversified.
Company details
Isconova was founded as a spin-off from SLU to further develop its ISCOM technology. The technology was invented by Professor Bror Morein. The company seeks to make it commercially available as a platform for vaccine development and improved off-the-shelf research adjuvants Isconova was a leading international vaccine adjuvant company. Isconova was developing vaccines together with partners in the human and veterinary markets. The first vaccine using Isconovas nano-particle Matrix technology, Equilis, Prequenza, was launched on the veterinary market in 2005. In the human market, a number of vaccines are under development with Isconovas third generation nano-particle, Matrix MTM. Isconovas partners included Crucell, Pfizer, Merck Co., The Jenner Institute, Genocea, and Evolva. In July 2013, the company was acquired by Novavax.
- Headquarters Uppsala, Sweden
- Stage Acquired
- SectorsHealthcare
- Website isconova.com
- Social LinkedIn X Facebook
- Acquired by Novavax (Jun 2013)
Funding Insights of Isconova
Isconova has successfully raised a total of $5.02M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.02 million completed in June 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.02M
- Total Rounds 1
- Last Round Series A — $5.02M
- First Round $5.02M
(Jun 2008)
- Investors Count 1
All 1 funding rounds of Isconova with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2008 | $5.02M | Series A | – | – |
2 investors in total: 2 institutional.
Investors in Isconova
Isconova has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Novavax and InnovationsKapital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| innkap.se | ||||
Novel vaccines are developed using nanoparticle and matrix adjuvant technology. | 1987 | novavax.com | Gaithersburg, United States |
Investor details for Isconova
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Isconova
Isconova has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nordic Vaccine.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Adjuvants and vaccine delivery systems were developed for needle-free administration. | nordic-vaccine.dk | Copenhagen, Denmark | 2001 | May 2011 | $667,471 |
Complete acquisition details for Isconova
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Isconova
4 dated milestones of Isconova across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Isconova is founded.
- Funding First funding round of $5.0M.
- Acquisition Acquires Nordic Vaccine.
- Exit Acquired by Novavax.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Isconova
Isconova was founded in 1999 and raised its 1st funding round 9 years after it was founded.
Isconova is headquartered in Uppsala, Sweden. It is registered at Uppsala, Uppsala County, Sweden.
Isconova is a funded company, having raised a total of $5.02M across 1 funding round to date. The company's 1st funding round was a Series A of $5.02M, raised on Jun 2008.
Isconova was founded as a spin-off from SLU to further develop its ISCOM technology. The technology was invented by Professor Bror Morein. The company seeks to make it commercially available as a platform for vaccine development and improved off-the-shelf research adjuvants Isconova was a leading international vaccine adjuvant company. Isconova was developing vaccines together with partners in the human and veterinary markets. The first vaccine using Isconovas nano-particle Matrix technology, Equilis, Prequenza, was launched on the veterinary market in 2005. In the human market, a number of vaccines are under development with Isconovas third generation nano-particle, Matrix MTM. Isconovas partners included Crucell, Pfizer, Merck Co., The Jenner Institute, Genocea, and Evolva. In July 2013, the company was acquired by Novavax.
Isconova has made 1 acquisition, including Nordic Vaccine.
Isconova has 2 investors. Key investors include Novavax, and InnovationsKapital.
Yes. Isconova was acquired by Novavax in June 2013.